What is Chardan Capital's Estimate for PRQR FY2025 Earnings?

ProQR Therapeutics (NASDAQ:PRQR - Free Report) - Research analysts at Chardan Capital raised their FY2025 earnings per share (EPS) estimates for shares of ProQR Therapeutics in a report issued on Monday, March 24th. Chardan Capital analyst K. Nakae now expects that the biopharmaceutical company will earn ($0.33) per share for the year, up from their previous forecast of ($0.34). Chardan Capital currently has a "Buy" rating and a $4.00 target price on the stock. The consensus estimate for ProQR Therapeutics' current full-year earnings is ($0.31) per share.

PRQR has been the subject of several other research reports. Citigroup raised shares of ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 target price for the company in a report on Monday, March 10th. Oppenheimer initiated coverage on ProQR Therapeutics in a research note on Friday, January 10th. They issued an "outperform" rating and a $15.00 price objective for the company. HC Wainwright lifted their target price on ProQR Therapeutics from $10.00 to $12.00 and gave the company a "buy" rating in a research note on Friday, March 14th. Finally, JMP Securities restated a "market outperform" rating and issued a $8.00 price target on shares of ProQR Therapeutics in a research note on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $9.50.

Remove Ads

ProQR Therapeutics Stock Performance

Shares of PRQR traded down $0.03 during mid-day trading on Thursday, reaching $1.40. The stock had a trading volume of 323,303 shares, compared to its average volume of 563,274. The business has a fifty day moving average of $2.08 and a 200 day moving average of $2.60. The firm has a market cap of $147.30 million, a price-to-earnings ratio of -4.38 and a beta of 0.24. ProQR Therapeutics has a 12 month low of $1.40 and a 12 month high of $4.62.

Institutional Investors Weigh In On ProQR Therapeutics

A number of hedge funds have recently modified their holdings of the company. Alpine Global Management LLC acquired a new stake in ProQR Therapeutics during the 4th quarter worth approximately $39,000. Woodline Partners LP purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at about $9,426,000. Velan Capital Investment Management LP acquired a new position in shares of ProQR Therapeutics during the 4th quarter worth $107,000. Squarepoint Ops LLC boosted its stake in shares of ProQR Therapeutics by 16.3% during the 4th quarter. Squarepoint Ops LLC now owns 83,114 shares of the biopharmaceutical company's stock worth $220,000 after acquiring an additional 11,623 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in shares of ProQR Therapeutics by 512.8% during the 4th quarter. Two Sigma Investments LP now owns 383,134 shares of the biopharmaceutical company's stock worth $1,015,000 after buying an additional 320,614 shares during the last quarter. Hedge funds and other institutional investors own 32.65% of the company's stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).